Press Release: Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old
Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old Recommendation based on a ...
T-Net1d
Eupraxia Pharmaceuticals Announces Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company leveraging its proprietary DiffuSphere technology to ...
GlobalData on MSN1d
AstraZeneca’s Fasenra to challenge GSK’s Nucala in rare vasculitis after FDA nod
Before the FDA approved AstraZeneca’s Fasenra, Nucala was the only therapy for treating eosinophilic granulomatosis with ...
Pharmaceutical Technology11d
CALY-002 by Novartis for Eosinophilic Esophagitis: Likelihood of Approval
CALY-002 is under clinical development by Novartis and currently in Phase I for Eosinophilic Esophagitis. According to GlobalData, Phase I drugs for Eosinophilic Esophagitis have an 86% phase ...
FiercePharma2d
AstraZeneca's Fasenra plays catch-up with GSK's Nucala, gaining FDA nod for rare autoimmune disease
Fasenra was approved in 2017 but AZ came up short in its attempts to expand its label to chronic obstructive pulmonary ...
Yahoo Finance8d
Eupraxia reports positive data from eosinophilic esophagitis treatment trial
Eupraxia Pharmaceuticals has disclosed additional positive data from its Phase Ib/IIa RESOLVE clinical trial of EP-104GI in treating eosinophilic esophagitis (EoE). The multicentre, open-label ...
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Eosinophilic Esophagitis (EoE) in Children as Young as 1 Year Old
Recommendation based on a Phase 3 trial showing a significantly greater proportion of children on Dupixent achieved histological remission ...
KTLA9d
Eupraxia Pharmaceuticals Announces Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
A reduction in SDI is a positive outcome for the RESOLVE trial. 2. In the Eosinophilic Esophagitis Histology Scoring System, or EoEHSS, grade indicates the severity of each of the eight ...
Sanofi: Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old
Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old Recommendation based on a phase 3 study showing a significantly greater proportion ...